BNOX
Income statement / Annual
Last year (2024), Bionomics Limited's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Bionomics Limited's net income was -$15.49 B.
See Bionomics Limited’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
06/30/2024 |
06/29/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/29/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
| Operating Revenue |
$0.00
|
$20,000.00
|
$260,000.00
|
$0.00
|
$50,000.00
|
$3.82 M
|
$8.79 M
|
$20.79 M
|
$14.33 M
|
| Cost of Revenue |
$434,449.00 |
$13.06 M |
$11.05 M |
$4.32 M |
$4.02 M |
$8.52 M |
$18.69 M |
$18.62 M |
$18.45 M |
| Gross Profit |
-$434,449.00 |
-$12.63 M |
-$6.87 M |
-$3.62 M |
-$1.96 M |
-$3.35 M |
-$9.89 M |
$2.17 M |
-$4.13 M |
| Gross Profit Ratio |
0 |
-29.19 |
-1.64 |
-5.21 |
-0.95 |
-0.65 |
-1.12 |
0.1 |
-0.29 |
| Research and Development
Expenses |
$9.42 B
|
$19.61 M
|
$16.00 M
|
$5.76 M
|
$5.83 M
|
$8.98 M
|
$18.69 M
|
$18.62 M
|
$18.45 M
|
| General & Administrative
Expenses |
$8.47 B
|
$5.75 M
|
$5.11 M
|
$3.28 M
|
$2.53 M
|
$4.68 M
|
$6.86 M
|
$4.40 M
|
$5.61 M
|
| Selling & Marketing
Expenses |
$0.00
|
$146,759.00
|
$181,193.00
|
$954,120.00
|
$814,688.00
|
$851,002.00
|
$1.05 M
|
$1.99 M
|
$2.26 M
|
| Selling, General &
Administrative Expenses |
$8.47 B
|
$8.86 M
|
$7.66 M
|
$5.65 M
|
$4.85 M
|
$9.35 M
|
$7.91 M
|
$6.40 M
|
$7.87 M
|
| Other Expenses |
$0.00 |
$0.00 |
$6,674.00 |
$203,014.00 |
$200,284.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$17.89 B |
$32.00 M |
$21.61 M |
$11.92 M |
$9.06 M |
$19.18 M |
$8.44 M |
$6.37 M |
$8.28 M |
| Cost And Expenses |
$17.89 B |
$22.09 M |
$19.32 M |
$6.29 M |
$5.01 M |
$10.99 M |
$27.12 M |
$24.99 M |
$26.73 M |
| Interest Income |
$0.00 |
$480,000.00 |
$10,000.00 |
$10,000.00 |
$60,000.00 |
$280,000.00 |
$1.10 M |
$589,100.00 |
$497,429.00 |
| Interest Expense |
$0.00 |
$20,000.00 |
$30,000.00 |
$1.17 M |
$1.79 M |
$2.36 M |
$1.51 M |
$1.37 M |
$1.41 M |
| Depreciation &
Amortization |
$434,449.00
|
$778,248.00
|
$804,535.00
|
$1.27 M
|
$1.64 M
|
$1.22 M
|
$1.29 M
|
$1.31 M
|
$1.41 M
|
| EBITDA |
-$9.84 M
|
-$20.90 M
|
-$11.51 M
|
-$4.97 M
|
-$4.19 M
|
-$7.87 M
|
-$16.57 M
|
-$2.88 M
|
-$10.55 M
|
| EBITDA Ratio |
0 |
-41.31 |
-2.75 |
-10.06 |
-2.03 |
-1.52 |
-1.88 |
-0.14 |
-0.74 |
| Operating Income Ratio
|
0
|
-42.83
|
-2.91
|
-11.07
|
-2.5
|
-1.72
|
-2.02
|
-0.2
|
-0.84
|
| Total Other
Income/Expenses Net |
$17.88 B
|
-$2.99 M
|
-$3.01 M
|
$1.04 M
|
$4.85 M
|
$7.94 M
|
-$1.63 M
|
-$562,011.00
|
-$911,702.00
|
| Income Before Tax |
-$10.27 M |
-$32.05 M |
-$21.95 M |
-$8.88 M |
-$6.03 M |
-$9.91 M |
-$19.43 M |
-$4.79 M |
-$12.91 M |
| Income Before Tax Ratio
|
0
|
-49.34
|
-3.63
|
-9.57
|
-2.01
|
-1.44
|
-2.21
|
-0.23
|
-0.9
|
| Income Tax Expense |
-$87.32 M |
-$210,000.00 |
-$190,000.00 |
-$190,000.00 |
-$210,000.00 |
-$240,000.00 |
$859,399.00 |
$401,641.00 |
$545,094.00 |
| Net Income |
-$15.49 B |
-$31.85 M |
-$21.76 M |
-$8.70 M |
-$7.12 M |
-$9.67 M |
-$18.57 M |
-$5.19 M |
-$12.36 M |
| Net Income Ratio |
0 |
-49.03 |
-3.59 |
-9.37 |
-1.94 |
-1.41 |
-2.11 |
-0.25 |
-0.86 |
| EPS |
-1.02 |
-0.0217 |
-0.0161 |
-0.0112 |
-0.0131 |
-0.0186 |
-0.0693 |
-0.0194 |
-0.0487 |
| EPS Diluted |
-1.02 |
-0.0217 |
-0.0161 |
-0.0112 |
-0.0131 |
-0.0186 |
-0.0693 |
-0.0194 |
-0.0482 |
| Weighted Average Shares
Out |
$9.99 M
|
$1.47 B
|
$1.35 B
|
$779.88 M
|
$544.83 M
|
$521.26 M
|
$267.94 M
|
$267.42 M
|
$254.03 M
|
| Weighted Average Shares
Out Diluted |
$9.99 M
|
$1.47 B
|
$1.35 B
|
$779.88 M
|
$544.83 M
|
$521.26 M
|
$267.94 M
|
$267.42 M
|
$256.28 M
|
| Link |
|
|
|
|
|
|
|
|
|
